Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy

Madhurima Saha, Skylar A. Rizzo, Manashwi Ramanathan, Rylie M. Hightower, Katherine E. Santostefano, Naohiro Terada, Richard S. Finkel, Jonathan S. Berg, Nizar Chahin, Christina A. Pacak, Richard E. Wagner, Matthew S. Alexander, Isabelle Draper, Peter B. Kang

Research output: Contribution to journalArticle

Abstract

MEGF10 myopathy is a rare inherited muscle disease that is named after the causative gene, MEGF10. The classic phenotype, early onset myopathy, areflexia, respiratory distress and dysphagia, is severe and immediately life-threatening. There are no disease-modifying therapies. We performed a small molecule screen and follow-up studies to seek a novel therapy. A primary in vitro drug screen assessed cellular proliferation patterns in Megf10-deficient myoblasts. Secondary evaluations were performed on primary screen hits using myoblasts derived from Megf10-/- mice, induced pluripotent stem cell-derived myoblasts from MEGF10 myopathy patients, mutant Drosophila that are deficient in the homologue of MEGF10 (Drpr) and megf10 mutant zebrafish. The screen yielded two promising candidates that are both selective serotonin reuptake inhibitors (SSRIs), sertraline and escitalopram. In depth follow-up analyses demonstrated that sertraline was highly effective in alleviating abnormalities across multiple models of the disease including mouse myoblast, human myoblast, Drosophila and zebrafish models. Sertraline also restored deficiencies of Notch1 in disease models. We conclude that SSRIs show promise as potential therapeutic compounds for MEGF10 myopathy, especially sertraline. The mechanism of action may involve the Notch pathway.

Original languageEnglish (US)
Article numberddz064
Pages (from-to)2365-2377
Number of pages13
JournalHuman molecular genetics
Volume28
Issue number14
DOIs
StatePublished - Jul 15 2019

Fingerprint

Myoblasts
Serotonin Uptake Inhibitors
Muscular Diseases
Sertraline
Zebrafish
Drosophila
Multiple Abnormalities
Induced Pluripotent Stem Cells
Citalopram
Deglutition Disorders
Therapeutics
Cell Proliferation
Phenotype
Muscles
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Saha, M., Rizzo, S. A., Ramanathan, M., Hightower, R. M., Santostefano, K. E., Terada, N., ... Kang, P. B. (2019). Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy. Human molecular genetics, 28(14), 2365-2377. [ddz064]. https://doi.org/10.1093/hmg/ddz064

Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy. / Saha, Madhurima; Rizzo, Skylar A.; Ramanathan, Manashwi; Hightower, Rylie M.; Santostefano, Katherine E.; Terada, Naohiro; Finkel, Richard S.; Berg, Jonathan S.; Chahin, Nizar; Pacak, Christina A.; Wagner, Richard E.; Alexander, Matthew S.; Draper, Isabelle; Kang, Peter B.

In: Human molecular genetics, Vol. 28, No. 14, ddz064, 15.07.2019, p. 2365-2377.

Research output: Contribution to journalArticle

Saha, M, Rizzo, SA, Ramanathan, M, Hightower, RM, Santostefano, KE, Terada, N, Finkel, RS, Berg, JS, Chahin, N, Pacak, CA, Wagner, RE, Alexander, MS, Draper, I & Kang, PB 2019, 'Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy', Human molecular genetics, vol. 28, no. 14, ddz064, pp. 2365-2377. https://doi.org/10.1093/hmg/ddz064
Saha M, Rizzo SA, Ramanathan M, Hightower RM, Santostefano KE, Terada N et al. Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy. Human molecular genetics. 2019 Jul 15;28(14):2365-2377. ddz064. https://doi.org/10.1093/hmg/ddz064
Saha, Madhurima ; Rizzo, Skylar A. ; Ramanathan, Manashwi ; Hightower, Rylie M. ; Santostefano, Katherine E. ; Terada, Naohiro ; Finkel, Richard S. ; Berg, Jonathan S. ; Chahin, Nizar ; Pacak, Christina A. ; Wagner, Richard E. ; Alexander, Matthew S. ; Draper, Isabelle ; Kang, Peter B. / Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy. In: Human molecular genetics. 2019 ; Vol. 28, No. 14. pp. 2365-2377.
@article{7f00b7bc0bb7403292b1a30183feb2f8,
title = "Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy",
abstract = "MEGF10 myopathy is a rare inherited muscle disease that is named after the causative gene, MEGF10. The classic phenotype, early onset myopathy, areflexia, respiratory distress and dysphagia, is severe and immediately life-threatening. There are no disease-modifying therapies. We performed a small molecule screen and follow-up studies to seek a novel therapy. A primary in vitro drug screen assessed cellular proliferation patterns in Megf10-deficient myoblasts. Secondary evaluations were performed on primary screen hits using myoblasts derived from Megf10-/- mice, induced pluripotent stem cell-derived myoblasts from MEGF10 myopathy patients, mutant Drosophila that are deficient in the homologue of MEGF10 (Drpr) and megf10 mutant zebrafish. The screen yielded two promising candidates that are both selective serotonin reuptake inhibitors (SSRIs), sertraline and escitalopram. In depth follow-up analyses demonstrated that sertraline was highly effective in alleviating abnormalities across multiple models of the disease including mouse myoblast, human myoblast, Drosophila and zebrafish models. Sertraline also restored deficiencies of Notch1 in disease models. We conclude that SSRIs show promise as potential therapeutic compounds for MEGF10 myopathy, especially sertraline. The mechanism of action may involve the Notch pathway.",
author = "Madhurima Saha and Rizzo, {Skylar A.} and Manashwi Ramanathan and Hightower, {Rylie M.} and Santostefano, {Katherine E.} and Naohiro Terada and Finkel, {Richard S.} and Berg, {Jonathan S.} and Nizar Chahin and Pacak, {Christina A.} and Wagner, {Richard E.} and Alexander, {Matthew S.} and Isabelle Draper and Kang, {Peter B.}",
year = "2019",
month = "7",
day = "15",
doi = "10.1093/hmg/ddz064",
language = "English (US)",
volume = "28",
pages = "2365--2377",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "14",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy

AU - Saha, Madhurima

AU - Rizzo, Skylar A.

AU - Ramanathan, Manashwi

AU - Hightower, Rylie M.

AU - Santostefano, Katherine E.

AU - Terada, Naohiro

AU - Finkel, Richard S.

AU - Berg, Jonathan S.

AU - Chahin, Nizar

AU - Pacak, Christina A.

AU - Wagner, Richard E.

AU - Alexander, Matthew S.

AU - Draper, Isabelle

AU - Kang, Peter B.

PY - 2019/7/15

Y1 - 2019/7/15

N2 - MEGF10 myopathy is a rare inherited muscle disease that is named after the causative gene, MEGF10. The classic phenotype, early onset myopathy, areflexia, respiratory distress and dysphagia, is severe and immediately life-threatening. There are no disease-modifying therapies. We performed a small molecule screen and follow-up studies to seek a novel therapy. A primary in vitro drug screen assessed cellular proliferation patterns in Megf10-deficient myoblasts. Secondary evaluations were performed on primary screen hits using myoblasts derived from Megf10-/- mice, induced pluripotent stem cell-derived myoblasts from MEGF10 myopathy patients, mutant Drosophila that are deficient in the homologue of MEGF10 (Drpr) and megf10 mutant zebrafish. The screen yielded two promising candidates that are both selective serotonin reuptake inhibitors (SSRIs), sertraline and escitalopram. In depth follow-up analyses demonstrated that sertraline was highly effective in alleviating abnormalities across multiple models of the disease including mouse myoblast, human myoblast, Drosophila and zebrafish models. Sertraline also restored deficiencies of Notch1 in disease models. We conclude that SSRIs show promise as potential therapeutic compounds for MEGF10 myopathy, especially sertraline. The mechanism of action may involve the Notch pathway.

AB - MEGF10 myopathy is a rare inherited muscle disease that is named after the causative gene, MEGF10. The classic phenotype, early onset myopathy, areflexia, respiratory distress and dysphagia, is severe and immediately life-threatening. There are no disease-modifying therapies. We performed a small molecule screen and follow-up studies to seek a novel therapy. A primary in vitro drug screen assessed cellular proliferation patterns in Megf10-deficient myoblasts. Secondary evaluations were performed on primary screen hits using myoblasts derived from Megf10-/- mice, induced pluripotent stem cell-derived myoblasts from MEGF10 myopathy patients, mutant Drosophila that are deficient in the homologue of MEGF10 (Drpr) and megf10 mutant zebrafish. The screen yielded two promising candidates that are both selective serotonin reuptake inhibitors (SSRIs), sertraline and escitalopram. In depth follow-up analyses demonstrated that sertraline was highly effective in alleviating abnormalities across multiple models of the disease including mouse myoblast, human myoblast, Drosophila and zebrafish models. Sertraline also restored deficiencies of Notch1 in disease models. We conclude that SSRIs show promise as potential therapeutic compounds for MEGF10 myopathy, especially sertraline. The mechanism of action may involve the Notch pathway.

UR - http://www.scopus.com/inward/record.url?scp=85068959639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068959639&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddz064

DO - 10.1093/hmg/ddz064

M3 - Article

VL - 28

SP - 2365

EP - 2377

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 14

M1 - ddz064

ER -